Immutep (IMMP) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.
The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated "significant improvement" in overall response rate.
The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.
Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.
Price: 2.08, Change: +0.21, Percent Change: +11.23
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。